Medical dermatology company Botanix Pharmaceuticals (ASX:BOT) has announced the appointment of Dr Michael Thurn, head of its Australian operations, as executive director.
Founder and executive director of Botanix, Matt Callahan, said: “On behalf of the Board, I would like to thank Dr Thurn for his outstanding contribution to building Botanix’s product portfolio over the past two years. We are pleased to welcome someone of Dr Thurn’s expertise and experience to the Botanix Board. His complementary skillset will support our development activities and further strengthens the leadership of Botanix.”
Dr Thurn has over two decades of experience in the life sciences and biotechnology industry and has accumulated extensive knowledge in drug regulation, drug discovery, pre-clinical and clinical development across dermatology in Australia and the United States.
He has held various senior executive, managerial and Board positions in both listed and private companies and brings unique experience, highly relevant technical knowledge and complementary skillset to the Botanix Board.
Previously, Dr Thurn has worked with the Therapeutic Goods Administration in Australia, led the clinical development of a topical acne treatment through to completion of Phase 2 clinical trial and also led Spinifex Pharmaceuticals, which was sold to Novartis in a $700 million transaction.